BioLineRx Presents Positive Preclinical Results in Treatment for AML Patients with FLT3 Mutations

The results for this additional indication for BKT-140/BL-8040 will be presented at the Society of Hematologic Oncology (SOHO) Annual Meeting. BKT-140/BL-8040 is also undergoing Phase 2 study in AML, with the final results expected in early 2015. It is also in a Phase 1 study in stem cell mobilization, with the results expected by the end of 2014 or early 2015.

Read More